Drug intelligence / Profile preview

MF268

Development stage: Unknown
Lead developer: Mediolanum
Modality: Small Molecules
Administration: Oral

Overview

MF268 is a small molecule cholinesterase inhibitor of the carbamate type that acts as a pseudo-reversible inhibitor. It interacts with both the catalytic and regulatory anionic sites of cholinesterase enzymes. Preclinical studies have shown that it increases extracellular acetylcholine levels in the cortex and has memory-enhancing activity in animal models. The compound belongs to the class of morpholines and was developed for potential use in Alzheimer's disease[1][2][3][4][5].

Other names: MF-268MF268MF 268MF 268 bitartrateMF268 bitartrateMF-268 bitartrate

Targets

ButyrylcholinesteraseAcetylcholinesterase

Beyond the preview

Go deeper on MF268.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MF268.

Explore the full profile